Oaknin A, Rubio M J, Redondo A, De Juan A, Cueva Bañuelos J F, Gil-Martin M, Ortega E, Garcia-Arias A, Gonzalez-Martin A, Bover I
Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Ps Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Clin Transl Oncol. 2015 Dec;17(12):1036-42. doi: 10.1007/s12094-015-1452-2. Epub 2015 Dec 9.
Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC.
宫颈癌（CC）是全球第二大常见癌症，与高危型人乳头瘤病毒感染密切相关。尽管筛查项目已使发达国家因宫颈癌导致的发病率和死亡率显著降低，但在不发达国家，它仍是一个重要的死亡原因。临床分期仍然是最关键的预后因素。在早期阶段，主要治疗方法是手术或放疗，而同步放化疗是局部晚期阶段的传统治疗方法。在复发性或转移性宫颈癌的情况下，化疗联合贝伐单抗首次使总生存期延长至12个月以上。因此，大多数肿瘤学家认为该方案是转移性/复发性宫颈癌的新护理标准。
